University of Pittsburgh

Alzheimer Disease Research Center

The University of Pittsburgh Alzheimer Disease Research Center (ADRC) is one of the nation’s leading research centers specializing in the diagnosis of Alzheimer’s disease and related disorders.

Memory Evaluation

Donate Now

Youth Movement Against Alzheimer’s chapter (YMAA) at Pitt started by pre-med student

YMAA was charted in 2015 and is the largest youth-led Alzheimer’s 501 (c)(3) non-profit in the nation.

Seeking individuals with Alzheimer’s disease who experience agitation

The Escitalopram for Agitation in Alzheimer's Disease (S-CitAD) study is a 12-week trial of escitalopram taking place at the University of Pittsburgh Alzheimer Disease Research Center. The S-CitAD Study is looking for volunteers who: Have been diagnosed with...

WQED Documentary “Stolen Years” Highlights Research Being Conducted at the University of Pittsburgh ADRC

Nearly two-thirds of Americans living with Alzheimer’s are women. Sixty percent of all Alzheimer’s caregivers are women.

BRiTE Wellness Program aims to help seniors with mild memory problems

The BRiTE (Brain Training and Exercise) Center mission is to promote the overall health and wellness of older adults who want to optimize their level of cognitive, social, and physical functioning.

Upcoming Events

The University of Pittsburgh Alzheimer Disease Research Center (ADRC) is one of the nation’s leading research centers specializing in the diagnosis of Alzheimer’s disease and related disorders. Through outpatient evaluations, participants and their families receive state-of-the-art diagnostic assessments and contribute to the scientific study of Alzheimer’s disease.

Our memory evaluation is an extensive diagnostic evaluation of individuals with suspected Alzheimer’s disease and other types of memory loss and/or cognitive impairment. The professionals at the ADRC understand that this is a stressful process for all and assure that individuals will be treated with sensitivity and respect.

Dementia with Lewy Bodies Consortium

Description: The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers improve the diagnosis, care, and treatment of patients with this disease.

Study Length: 5 years

Study Requirements:
Age 40-90
Diagnosis of Lewy Body Dementia (DLB) or high likelihood
A study partner who will accompany you to all study visits

Contact:
Donna Simpson at 412-692-2717 or simpsondm@upmc.edu or
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

Alzheimer’s Disease Neuroimaging Initiative – 3 (ADNI3)

Description: The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD) from its earliest stages. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection. For more information about the ADNI3 study visit http://www.adni-info.org/

Study Length: up to 5 years

Study Requirements:
55-90 years of age
Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease
A study partner who will accompany you to all study visits

Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

T2 Protect AD

Description: The study is designed to determine if troriluzole can protect against, slow down, and potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses.

Study Length: 1 year

Study Requirements:
55-85 years of age
Diagnosis of Alzheimer’s disease
A study partner who will accompany you to all study visits

Contact:
Thomas Baumgartner, Jr. at 412-692-2716 or baumgartnertc@upmc.edu or MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)

Description: The study is designed to examine the efficacy and safety of escitalopram in combination with a psychosocial intervention (PSI) as treatment for agitation in AD patients.

Study Length: 6 months

Study Requirements:
Diagnosis of Alzheimer’s disease with significant agitation/aggression
A study partner who will accompany you to all study visits

Contact:
Patricia Henderson 412-692-2703 or hendersonpl@upmc.edu or

FORAging – Facilitating Optimal Routines in Aging

Description: This study is looking at ways to minimize problems with everyday tasks by using a new strategy.

Study Length: 12 months

Study Requirements:
60 years of age AND
Having difficulty managing daily tasks

Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

Andy Warhol Museum

The ADRC has been working with the Andy Warhol Museum, offering a program for ADRC participants with memory loss to tour the museum, take part in an arts and crafts activity, and to foster discussions about art.

Pathways Newsletter

The Summer 2019 edition of the Pathways Newsletter is now available.

Memory Eval
Clinical Trials
Faculty & Staff
News
Events
FAQ

412-692-2700

Mailing Address

Alzheimer’s Disease Research Center
UPMC Montefiore, 4th floor, suite 421
200 Lothrop Street
Pittsburgh, PA 15213
FAX: 412-692-2710